DOP34 Comparison of the risk of clinical recurrence after ileocolonic resection for Crohn's Disease for modified Rutgeerts' score i2a and i2b categories: Individual patient data meta-analysis

Riviere, P.(1);Pekow, J.(2);Hammoudi, N.(3);Wils, P.(4);De Cruz, P.(5);Wang, C.(6);Mañosa, M.(7);Ollech, J.(2);Allez, M.(3);Nachury, M.(4);Kamm, M.(5);Maya, A.(2);Ferrante, M.(8);Buisson, A.(9);Singh, S.(10);Laharie, D.(1);Momar, D.(11);Fumery, M.(12);

(1)Bordeaux University Hospital, Gastroenterology unit, Pessac, France;(2)University of Chicago, Gastroenterology, Chicago, United States;(3)Hôpital Saint-Louis, Gastroenterology, Paris, France;(4)Lille University Hospital, Gastroenterology, Lille, France;(5)The Austin Hospital, Gastroenterology, Melbourne, Australia;(6)Mount Sinai Hospital, Gastroenterology, New York, United States;(7)Hospital Germans Trias, Gastroenterology, Badalona, Spain;(8)Leuven University Hospitals, Gastroenterology, Leuven, Belgium;(9)Clermont Ferrand University Hospitals, Gastroenterology, Clermont Ferrand, France;(10)UC San Diego Health, Gastroenterology, San Diego, United States;(11)Amiens University Hospitals, Statistics, Amiens, France;(12)Amiens University Hospitals, Gastroenterology, Amiens, France;

Background

The modified Rutgeerts' score (mRS) differentiates i2a – lesions confined to the anastomosis – and i2b – neoterminal ileum lesions – categories. Its relevance for therapeutic management of Crohn's disease (CD) patients after ileocolonic resection is still debated. Our objective was to compare the postoperative recurrence (POR) risk in patients with a mRS i2a or i2b score using an individual patient data meta-analysis.

Methods

We conducted a systematic literature search of Medline, Embase and abstracts from international conferences (until July 2020) to identify all relevant studies reporting the risk of clinical and/or surgical POR and the i2a/i2b status in the year following ileocolonic resection. Initial datasets were obtained from the corresponding authors. Time from endoscopy to clinical and surgical POR was estimated using Kaplan-Meier method. The association between time to event and mRS was evaluated using a mixed Cox with centre as the random effect.

Results

From the 17 studies identified, 7 published between 2008 and 2019 (cohort studies, n=4; clinical trials, n=2) corresponding to a total of 400 patients (median (InterQuartileRange) age at surgery 34 (26,47) years; 52% female) were included. In the year following ileocolonic resection, 189 (47%) patients displayed an i2a mRS and 211 (53%) an i2b. In the i2b group, we observed more male patients (56% versus 41%, p=0.01), more patients with previous ileocolonic resection (31% versus 21%, p=0.03) and temporary ileostomy (14% versus 6%, p=0.03) and an immunosuppressant or antiTNF therapy was more frequently initiated after endoscopy (42% versus 26%, p<0.01 and 36% versus 54%, p<0.01, respectively). The risk of clinical POR at 1, 3 and 5 years was 11% [6%-15%], 25% [18%-32%] and 36% [27%-43%] in the i2a group and 9% [5%-13%], 33% [26%-41%] and 47% [39%-56%] in the i2b group (p=0.63, p=0.12, et p=0.05 respectively). No significant difference was observed in terms of time to clinical POR (Hazard Ratio (HR)=1.27; Confidence Interval 95% [0.91,1.76]; p=0.16) (Figure 1) or surgical POR (HR=0.94; CI95% [0.44,2.00]; p=0.87). After exclusion of patients having initiated an immunosuppressant or a biologic in the 3 months after endoscopy (remaining cohort, n=361), no difference was observed in terms of clinical POR (HR=1.29 [0.92,1.80]; p=0.13) or surgical POR (HR=0.85 [0.39,1.84]; p=0.68).

Conclusion

In this individual patient data meta-analysis, no difference is observed between i2a and i2b mRS subcategories in terms of clinical, surgical or endoscopic POR. Limits of the mRS may explain this lack of predictive value.